NCT07182721View on ClinicalTrials.gov

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

February 1, 2029

Conditions
HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSKB264Inetetamab
Interventions
DRUG

SKB264 Plus Inetetamab

SKB264: 5 mg/kg administered on Day 1 of each 2-week cycle. Inetetamab: an initial loading dose of 6 mg/kg is administered, followed by subsequent maintenance doses of 4 mg/kg. Dosing occurs on Day 1 of each 2-week cycle.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER